Avella Newsroom

January 1, 1970|
Limiting the Distribution of Oncology Drugs
July 23, 2018| CATEGORIES: Specialty Pharmacy , Oncology , limited distribution drugs

The following article was written by Avella's EVP of Clinical & Quality Assurance, Eric Sredzinski, and published in Specialty Pharmacy Times.

Oncology is already among the top therapeutic classes in specialty pharmacy.1 Experts say that drugs to fight cancer will continue to dominate the next wave of FDA approvals and enter the market at a rapid pace. Yet specifically how these medications are delivered to patients is also expected to evolve over time. This is especially true as manufacturers look to partner with specialty pharmacies that possess highly specific expertise in supporting patients with cancer and their complex treatment regimens.

Avella Selected by Array BioPharma Inc. to Distribute BRAFTOVI (encorafenib) and MEKTOVI (binimetinib)
June 27, 2018| CATEGORIES: Oncology , Cancer , Press Release

The specialty pharmacy will give patients access to this important new FDA-approved combination therapy for patients with advanced BRAF melanoma.

Phoenix, AZ -- Avella has announced that it will distribute BRAFTOVI™ (encorafenib) and MEKTOVI® (binimetinib), a combination therapy recently FDA approved for patients for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation, as detected by an FDA-approved test. 

The Leukemia & Lymphoma Society (LLS) Names Avella Executive Hamilton Baiden as the Corporate Walk Chair for Greater Phoenix Light The Night
March 29, 2018| CATEGORIES: Avella , Oncology , LLS , Press Release

Phoenix, AZ – The Arizona Chapter of The Leukemia & Lymphoma Society (LLS) announced today that Avella Specialty Pharmacy Executive Vice President Hamilton Baiden will serve as the Corporate Walk Chair of the 2018 Greater Phoenix Light The Night.

Avella Selected by AstraZeneca to Distribute CALQUENCE® (acalabrutinib)
October 31, 2017| CATEGORIES: Oncology , Press Release

The specialty pharmacy will provide access to this FDA-approved, second-generation treatment for mantle cell lymphoma

Avella Releases an In-Depth Outlook on Oncology Report for 2017
April 19, 2017| CATEGORIES: Oncology , Press Release

Avella Specialty Pharmacy has issued its Outlook on Oncology report, a fact-based analysis that depicts the current state of the oncology industry and explores the trends, opportunities and new developments affecting cancer care delivery. The new white paper is available for download at

The data-rich report details how many of the changes taking place in the healthcare industry as a whole are specifically impacting the oncology space. One example cited is the real-time information exchange happening between healthcare stakeholders, which is enabling greater coordination of care for oncology patients. In a similar manner, new oncology-focused Accountable Care Organizations (ACOs) are fostering greater collaboration among payers, providers and pharmacies.

Specialty Pharmacies Transforming Cancer Care
February 21, 2017| CATEGORIES: Specialty Pharmacy , Oncology , Cancer , Press Mention
As the model of collaborative healthcare expands and grows, every person who participates in patient care will have a distinct role to play to improve patient outcomes. Specialty pharmacies are increasingly bearing the charge of dispensing, distribution reimbursement, case management, and other services that serve a patient’s specific disease needs.

From adherence management to communicating with physicians, coordinating financial assistance, and managing prior authorization, specialty pharmacies offer patients a variety of comprehensive services. At the Patient-Centered Oncology Care® meeting, held November 17-18, 2016, in Baltimore, J. Ike Nicoll, President, The Morrison Group, and Joshua A. Rademacher, MBA, executive vice president, Enterprise Solutions and Business Development, at Avella Specialty Pharmacy, spoke to pairing novel cancer treatments with high-touch and high-technology support. 
Avella selected by Clovis Oncology to distribute RUBRACA (rucaparib)
December 20, 2016| CATEGORIES: Oncology , Press Release

New therapy gives oncologists a powerful treatment option for patients with ovarian cancer

Avella has announced that it has been selected by Clovis Oncology to distribute RUBRACATM, an oral therapy for ovarian cancer. The drug was recently approved by the FDA for patients with advanced ovarian cancer who have previously received two types of chemotherapy agents.

Avella Purchases Compounding Provider Oncology Plus
November 18, 2016| CATEGORIES: Oncology , Press Mention
Avella Specialty Pharmacy has closed on its acquisition of Oncology Plus LLC, a Florida-based provider of patient-specific compounded chemotherapeutics and supportive drugs to oncology practices and hospitals. Oncology Plus provides custom, unit dose, patient-specific chemotherapy drugs for IV and other specialized administration to hematology/oncology patients in physician practice and hospital settings.
Coyotes to Host Hockey Fights Cancer Night on Nov. 19
November 15, 2016| CATEGORIES: Oncology , Press Mention
The Arizona Coyotes announced today that the team will host its annual Hockey Fights Cancer Night, presented by Avella Specialty Pharmacy, on Saturday, Nov. 19, when the Coyotes face off against the San Jose Sharks. Game time is 6 p.m. at Gila River Arena.
Avella Specialty Pharmacy acquires Oncology Plus
November 15, 2016| CATEGORIES: Oncology , Press Mention
On the heels of its announcement that it had hired a new medical advisor, Avella Specialty Pharmacy on Monday announced that it had acquired Oncology Plus, a Tampa, Fla.-based provider of patient-specific compounded therapies. Avella said that the acquisition would further its strategic vision to become the nation’s leading omni-site specialty pharmacy and add breadth to its compounding and oncology-focused capabilities and offerings.
News Alerts
If you would like to receive email updates from Avella Specialty Pharmacy, please complete the information below.
News Alerts
If you would like to receive email updates from Avella Specialty Pharmacy, please complete the information below.